Docetaxel is under clinical development by Zhuhai Beihai Biotech and currently in Phase III for Solid Tumor. According to GlobalData, Phase III drugs for Solid Tumor have a 40% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Docetaxel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Docetaxel (BH009) is under development for the treatment of solid tumors, head and neck squamous cell carcinoma (including oropharynx, oral cavity, hypopharynx, and larynx and ovarian cancer (including epithelial ovarian carcinoma, fallopian tube carcinoma, and primary peritoneal carcinoma). It is administered through intravenous route. The drug candidate acts by targeting tubulin.
The drug candidate is under development for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric cancer and triple negative breast cancer.
Zhuhai Beihai Biotech overview
Zhuhai Beihai Biotech is a pharmaceutical company that dedicated to the development of innovative tumor drugs with unmet clinical needs. The company is headquartered in China.
For a complete picture of Docetaxel’s drug-specific PTSR and LoA scores, buy the report here.